Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2006 Dec;55(12):1731-8.
doi: 10.1136/gut.2005.080754. Epub 2006 May 10.

Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations

A Lanas  1 , L A García-Rodríguez, M T Arroyo, F Gomollón, F Feu, A González-Pérez, E Zapata, G Bástida, L Rodrigo, S Santolaria, M Güell, C M de Argila, E Quintero, F Borda, J M Piqué; Asociación Española de Gastroenterología
Affiliations
Multicenter Study

Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations

A Lanas et al. Gut. 2006 Dec.

Abstract

Background: The risks and benefits of coxibs, non-steroidal anti-inflammatory drugs (NSAIDs), and aspirin treatment are under intense debate.

Objective: To determine the risk of peptic ulcer upper gastrointestinal bleeding (UGIB) associated with the use of coxibs, traditional NSAIDs, aspirin or combinations of these drugs in clinical practice.

Methods: A hospital-based, case-control study in the general community of patients from the National Health System in Spain. The study included 2777 consecutive patients with endoscopy-proved major UGIB because of the peptic lesions and 5532 controls matched by age, hospital and month of admission. Adjusted relative risk (adj RR) of UGIB determined by conditional logistic regression analysis is provided.

Results: Use of non-aspirin-NSAIDs increased the risk of UGIB (adj RR 5.3; 95% confidence interval (CI) 4.5 to 6.2). Among non-aspirin-NSAIDs, aceclofenac (adj RR 3.1; 95% CI 2.3 to 4.2) had the lowest RR, whereas ketorolac (adj RR 14.4; 95% CI 5.2 to 39.9) had the highest. Rofecoxib treatment increased the risk of UGIB (adj RR 2.1; 95% CI 1.1 to 4.0), whereas celecoxib, paracetamol or concomitant use of a proton pump inhibitor with an NSAID presented no increased risk. Non-aspirin antiplatelet treatment (clopidogrel/ticlopidine) had a similar risk of UGIB (adj RR 2.8; 95% CI 1.9 to 4.2) to cardioprotective aspirin at a dose of 100 mg/day (adj RR 2.7; 95% CI 2.0 to 3.6) or anticoagulants (adj RR 2.8; 95% CI 2.1 to 3.7). An apparent interaction was found between low-dose aspirin and use of non-aspirin-NSAIDs, coxibs or thienopyridines, which increased further the risk of UGIB in a similar way.

Conclusions: Coxib use presents a lower RR of UGIB than non-selective NSAIDs. However, when combined with low-dose aspirin, the differences between non-selective NSAIDs and coxibs tend to disappear. Treatment with either non-aspirin antiplatelet or cardioprotective aspirin has a similar risk of UGIB.

PubMed Disclaimer

Conflict of interest statement

Funding: This study was made possible by funds from grant C03/02 from the National Institute of Research Carlos III and by unrestricted grants provided by Pfizer Spain, Merck Spain, AstraZeneca Spain, Uriach Laboratories and Rottapharm to the Spanish Association of Gastroenterology (AEG). These contributors have not had a role in the conduction of the study, the interpretation of data or writing of the manuscript.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Wolfe M M, Lichtenstein D R, Singh G. Gastrointestinal toxicity of nonsteroidal anti‐inflammatory drugs. N Engl J Med 19993401888–1899. - PubMed
    1. Brooks P, Emery P, Evans J F.et al Interpreting the clinical significance of the differential inhibition of cyclooxygenase‐1 and cyclooxygenase‐2. Rheumatology (Oxford) 19998779–788. - PubMed
    1. Bombardier C, Laine L, Reicin A.et al Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 20003431520–1528. - PubMed
    1. Silverstein F E, Faich G, Goldstein J L.et al Gastrointestinal toxicity with celecoxib vs nonsteroidal anti‐inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long‐term Arthritis Safety Study. JAMA 20002841247–1255. - PubMed
    1. Schnitzer T J, Burmester G R, Mysler E.et al Comparison of lumiracoxib with naproxen and ibuporfen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications:randomised controlled trial. Lancet 2004364665–674. - PubMed

Publication types